A user plans to order Pyrilutamide for hair loss after losing ground on finasteride. Another user advises against buying from Hairliciously, suggesting Amazon instead.
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
Dutasteride, finasteride, and minoxidil are considered the top hair loss treatments. Other suggested treatments include Nizoral shampoo, tretinoin, pyrilutamide, zinc, biotin, and low light laser therapy, though opinions on their effectiveness vary.
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
A 24-year-old user tried finasteride, oral minoxidil, and dutasteride for hair loss but saw no improvement and was advised by their dermatologist to accept baldness. Other users suggested alternative treatments like RU58841, pyrilutamide, microneedling, and checking for underlying conditions or lifestyle factors.
Alternatives to finasteride for hair loss include minoxidil, alfatrodial, fluridil, pyrilutamide, and Nizoral. These treatments may not be as effective as finasteride but can help slow hair loss progression.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Users discuss whether Koshine reduces sebum and scalp itchiness. Some report reduced sebum and seborrheic dermatitis, while others debate the effectiveness of anti-androgens like RU58841 for hair loss.
The user has been on 1mg finasteride for a year, experiencing low libido and moderate erectile issues. They are considering using Cialis daily with finasteride long term to address these side effects.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
Minoxidil 5% alone is not enough for significant hair regrowth; combining it with finasteride or dutasteride is advised. A hair transplant might be needed, depending on baldness extent and donor area quality.
The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.
Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.
A user is seeking advice on adding dutasteride to their finasteride regimen to stop DHT-related scalp itch. They have tried selenium sulfide and ketoconazole shampoos with temporary success.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
Guyman567 has been using oral finasteride and topical minoxidil for years but continues to experience hair loss and thinning, which has affected his confidence. He has tried various treatments including topical finasteride, microneedling, and vitamins, and is considering a hair transplant but is concerned about ongoing hair loss.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
The user is considering whether to continue their hair loss treatment, which includes finasteride, minoxidil spray, keto shampoo, and dermarolling. Suggestions include increasing minoxidil application, adding multivitamins, improving sleep, and possibly switching to dutasteride, while the consensus is to keep going with the treatment.
A user who has been taking finasteride, minoxidil, and microneedling for one year with no results, and the replies discuss other treatments, including dutasteride, which is feared due to potential side effects.
Long-term finasteride users report maintaining hair and experiencing regrowth, with some using it for over 20 years. Combining finasteride with minoxidil or hair transplants can improve results.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.